Skip to main content

Table 2 Antimicrobial resistance of Escherichia coli isolates to the tested antibiotics

From: Shifting trends in bacteriology and antimicrobial resistance among gastrointestinal fistula patients in China: an eight-year review in a tertiary-care hospital

Resistance rate (%)

Isolate/Antibiotics

2008–2011

2012–2015

Total

P for Trend Test

All Escherichia coli

 AMK

7.78

14.16

11.33

0.154

 AMP

97.92

96.49

97.14

0.537

 SAM

81.97

87.93

85.88

0.279

 TZP

23.47

25.00

24.30

0.795

 CZO

92.55

91.30

91.87

0.742

 CAZ

81.82

69.83

75.35

0.042

 FEP

75.51

62.07

68.22

0.035

 IPM

14.29

25.86

20.56

0.037

 CIP

90.16

79.13

82.95

0.064

ESBL+

 AMK

6.78

12.33

9.85

0.287

 AMP

100.00

100.00

100.00

 SAM

77.78

93.15

88.07

0.020

 TZP

20.31

6.85

13.14

0.020

 SXT

84.21

73.61

77.27

0.207

 CZO

100.00

100.00

100.00

 CAZ

89.23

68.49

78.26

0.003

 FEP

81.25

60.27

70.07

0.007

 IPM

12.31

8.22

10.14

0.427

 CIP

86.11

80.82

82.57

0.494

ESBL-

 AMK

6.67

16.22

13.46

0.361

 AMP

88.24

89.74

89.29

0.867

 SAM

77.78

77.50

77.55

0.986

 ZP

35.29

57.50

50.88

0.125

 SXT

88.89

67.50

71.43

0.199

 CZO

58.82

74.36

69.64

0.245

 CTT

28.57

70.00

63.83

0.035

 CAZ

52.94

70.00

64.91

0.217

 FEP

52.94

62.50

59.65

0.501

 IPM

43.75

57.50

53.57

0.351

 CIP

88.89

77.50

79.59

0.444

Not all tested antibiotics are listed

  1. AMK Amikacin, AMP Ampicillin, SAM Ampicillin/Sulbactam, CAZ Ceftazidime, efepime, CTT Cefotetan, CZO Cefazolin, IPM Imipenem, TZP Piperacillin-Tazobactam, CIP Ciprofloxacin
  2. Data in boldface reflected p values < 0.05